Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 822 across all filing types
Latest filing 2017-09-06 Regulatory Filings
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Immediate Report
Regulatory Filings Classification · 1% confidence The document is a press release dated September 6, 2017, announcing a collaboration between Kamada Ltd. and BGN Technologies regarding advanced research on Alpha-1 Antitrypsin (AAT). It details the scope of the research, quotes the CEO and a lead researcher, and includes standard 'About' sections and a 'Cautionary Note Regarding Forward-Looking Statements'. This type of announcement, focusing on strategic business development, research partnerships, and operational updates rather than mandatory periodic financial disclosures (like 10-K or IR) or specific shareholder actions (like DEF 14A or DVA), most closely aligns with a general corporate announcement. Since there is no specific category for 'Research Collaboration Announcement' or 'Press Release', and it is not a formal regulatory filing like a 10-K or an earnings release (ER), it falls best under the general regulatory/corporate announcement category, RNS, or potentially a general Investor Relations document. Given the context of a news announcement about business operations, RNS (Regulatory Filings/Announcements) is the most appropriate fallback for non-standard, material corporate news that isn't explicitly covered by other codes.
2017-09-06 English
Immediate Report
Regulatory Filings Classification · 1% confidence The document is very short (1852 characters) and explicitly states, "Attached hereto is a report on..." followed by a filename (*Professor_Eli_Lewis_isa.pdf*). This structure indicates that the document itself is an announcement about the publication of another report, rather than the full content of that report. The header mentions 'Immediate Report' and references the Israel Securities Authority (ISA) and Tel Aviv Stock Exchange (TASE), suggesting a regulatory filing. Since the content is an announcement of an attached document and does not fit specific categories like ER, IR, or 10-K, it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings), or potentially RPA (Report Publication Announcement). Given the context of immediate regulatory disclosure, RNS is the most appropriate general classification for miscellaneous regulatory announcements that don't fit the other specific types, although RPA is also plausible if the focus is purely on the publication act. I will select RNS as the broader regulatory filing category for this type of immediate disclosure notice.
2017-09-06 English
Immediate Report
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'FORM 6-K' and is filed 'For the Month of August, 2017'. Form 6-K is a report filed by foreign private issuers with the SEC to report material information not required to be reported on a Form 20-F. The content attached as Exhibit 99.1 is a 'News Release: Kamada Announces Full Exercise of Underwriters' Option to Purchase Additional Shares,' which details the completion of a public offering and the use of proceeds. This type of filing, which reports material, unscheduled information for a foreign private issuer, is generally classified under the broader category of Regulatory Filings (RNS) or sometimes as a Capital/Financing Update (CAP) if the focus is purely on the offering. Since the primary wrapper is the SEC Form 6-K, and the content is a material announcement (exercise of underwriter's option related to a financing), it fits best under the general 'Regulatory Filings' category (RNS) as it is a specific SEC form submission that doesn't map directly to the other defined categories like 10-K, ER, or IR. However, given the specific nature of the announcement (financing/share issuance), CAP is also a strong candidate. Since the document is a formal SEC filing (Form 6-K) containing a news release about the completion of a share offering, and RNS is the general regulatory fallback, I will prioritize RNS as the most accurate classification for an SEC Form 6-K submission unless the content is purely a financial supplement (XLSX) or a specific report (10-K, IR). Given the options, RNS is the most appropriate catch-all for a non-standard SEC report like 6-K.
2017-08-30 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is a short regulatory filing (1877 chars) dated 30/08/2017, issued by KAMADA LTD, and reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange. The key content states: "Attached hereto is a report on *Kamada Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares*" followed by a PDF filename. This structure—a brief announcement stating that a detailed report is attached or published—fits the definition of a Report Publication Announcement (RPA) according to Rule 2 (The 'Menu vs Meal' Rule). It is not the full report itself, but the notice of its publication.
2017-08-30 English
Other Report or Announcement
Regulatory Filings Classification · 1% confidence The document is explicitly titled "FORM 6-K" and is described as a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934." Form 6-K filings are used by foreign private issuers to report material information to the SEC, often mirroring the function of a Form 8-K in the US context. This type of filing is a general regulatory disclosure that does not fit neatly into the specific categories like 10-K (Annual Report), ER (Earnings Release), or DEF 14A (Remuneration). Therefore, the most appropriate classification based on the provided definitions is the general regulatory fallback category, RNS (Regulatory Filings). The document length is short (2763 chars), but it is the report itself, not an announcement of another report, so the RPA rule does not strictly apply here, making RNS the best fit for a Form 6-K.
2017-08-29 English
Other Report or Announcement
Report Publication Announcement Classification · 1% confidence The document is a regulatory filing submitted to the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE). It explicitly states, 'Other Report or Announcement' under 'Regulation 5 of the Securities Regulations'. Crucially, the text indicates that an attachment is included: 'Attached hereto is a report on *FDA Correspondences - August 2017*'. Since the document itself is very short (1784 characters) and serves primarily to announce the availability of an attached report (FDA Correspondences), it fits the definition of a Report Publication Announcement (RPA) rather than the report itself (like LTR or AR).
2017-08-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.